OR WAIT null SECS
July 01, 2026
Article
FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.
June 23, 2026
Video
A new 4-part microdrama series developed with real young adults living with food allergies aims to bridge the gap between clinical management and everyday life.
June 16, 2026
Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.
June 15, 2026
Phase 3 VITESSE subgroup data show response rates of 46% to 48% in children with peanut allergy and concomitant asthma, atopic dermatitis, or food allergies, says David Fleischer, MD.
June 11, 2026
Douglas Mack, MD, discusses the upcoming phase 2 THRIVE trial assessing the Viaskin Peanut patch in infants aged 6 through 12 months with peanut allergy.
June 05, 2026
From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.
June 02, 2026
At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.
June 01, 2026
Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.
May 12, 2026
In this Q&A, Christopher Brooks, MD, discusses advancing research on intralymphatic immunotherapy for environmental and, more recently, food allergies.
May 11, 2026
In recognition of Food Allergy Awareness Month, Brooks discusses food challenges, omalizumab, oral immunotherapy, and persistent gaps in food allergy management.
